The global wound care market is projected to reach $25.2 billion by 2033, expanding from a $14.3 billion base. Clinical pressures are significant, with over 2.0 million U.S. hospitalizations for pressure ulcers in a single year.
Key Takeaways
- 2023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)
- Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033
- 2023 global wound care products market was valued at USD 10.2 billion
- In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)
- In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and older
- In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)
- Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)
- Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)
- Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.
- In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weeks
- In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressings
- In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard care
- FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)
- In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)
- In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)
The wound care market is expanding fast, reaching about $14.3B in 2023 and $25.2B by 2033.
Related reading
01 · Category
Market Size30 stats
01
2023 global wound care market size was estimated at about USD 14.3 billion (and forecasted to reach about USD 25.2 billion by 2033)
02
Wound care market was forecast to grow at a CAGR of 5.6% from 2024 to 2033
03
2023 global wound care products market was valued at USD 10.2 billion
04
The wound care products market is projected to reach USD 18.5 billion by 2032
05
Wound care products market projected CAGR is 6.6% from 2023 to 2032
06
Global advanced wound care market was valued at USD 8.9 billion in 2022
07
Advanced wound care market is expected to reach USD 16.6 billion by 2030
08
Advanced wound care market forecast CAGR is 7.4% from 2023 to 2030
09
2023 U.S. wound care market size was $5.1 billion
10
The U.S. wound care market is forecast to grow at a CAGR of 5.0% from 2024 to 2030
11
EU wound care market size was estimated at EUR 5.3 billion in 2023
12
Europe wound care market forecast CAGR was 4.9% from 2024 to 2030
13
Asia-Pacific wound care market size was estimated at USD 2.7 billion in 2023
14
Asia-Pacific wound care market projected CAGR was 6.2% from 2024 to 2030
15
Mexico wound care market size was estimated at USD 0.46 billion in 2023
16
Japan wound care market size was estimated at USD 1.9 billion in 2023
17
Brazil wound care market size was estimated at USD 1.1 billion in 2023
18
India wound care market size was estimated at USD 1.0 billion in 2023
19
China wound care market size was estimated at USD 3.2 billion in 2023
20
Global wound dressings market was valued at USD 4.0 billion in 2023
21
Global wound dressings market is expected to reach USD 6.2 billion by 2028
22
Global wound dressings market projected CAGR is 9.0% from 2024 to 2029
23
Global advanced wound care market size was USD 12.9 billion in 2023 (alternative estimate page)
24
Advanced wound care market is projected to reach USD 22.1 billion by 2032
25
Advanced wound care market projected CAGR is 6.8% from 2024 to 2032
26
Global medical adhesive market size was valued at $6.1 billion in 2022 (relevance to wound dressings/adhesives)
27
Medical adhesive market is projected to reach $9.8 billion by 2032
28
Medical adhesive market projected CAGR is 5.1% from 2023 to 2032
29
U.S. diabetic foot ulcers (DFU) market size estimated at $2.8 billion in 2023
30
Diabetic foot ulcer treatment market projected to reach $5.5 billion by 2032
Interpretation
Market Size Interpretation
The wound care market is set for steady expansion, with the global market projected to rise from about USD 14.3 billion in 2023 to roughly USD 25.2 billion by 2033 at a 5.6% CAGR, while advanced wound care and key adjacent segments like wound dressings and skin substitutes grow even faster.
02 · Category
User Adoption17 stats
01
In 2020, there were 2.0 million hospitalizations in the U.S. with a diagnosis of pressure ulcer (any-listed diagnosis)
02
In 2020, 74.4% of hospitalizations with a pressure ulcer diagnosis were in adults aged 65 years and older
03
In 2020, 58.1% of pressure ulcer hospitalizations were coded as stage 2 (as reported in the HCUP Fast Stats category breakdown)
04
In 2020, 19.8% of pressure ulcer hospitalizations were coded as stage 3
05
In 2020, 13.2% of pressure ulcer hospitalizations were coded as stage 4
06
In 2021, 37.0% of U.S. adults had hypertension
07
In 2022, 17.5 million U.S. adults had depression (age 18+)
08
In 2018, 8.5% of hospital patients had at least one pressure ulcer during hospitalization (hospital-acquired pressure ulcers)
09
In the NHS (England), pressure ulcers prevalence in 2021/22 was 5.7% (point prevalence survey)
10
In 2016, 4.3% of hospital patients in England were found to have a pressure ulcer (NHS prevalence survey figure)
11
In 2020, 28.0% of nursing home residents in the U.S. had pressure ulcers (long-stay nursing home assessments; figure reported in AHRQ-related summaries)
12
In 2021, 30-day readmission rate for patients after hospital discharge was 17.0% (readmissions can include wound-complication events)
13
In 2020, the prevalence of chronic venous insufficiency in the U.S. was 1–3% (commonly cited epidemiologic range; used as adoption driver)
14
In 2018, about 12.0% of people with diabetes reported a history of diabetic foot ulcers (survey-based estimate in published literature)
15
In 2020, 1 in 10 hospital patients had at least one pressure ulcer incident during the hospital stay (prevalence estimate in safety literature)
16
In 2021, 38.0% of U.S. adults had difficulty walking or climbing stairs (mobility limitation driver for pressure ulcer risk)
17
In 2019, nursing home prevalence for pressure ulcers in U.S. long-term care settings was about 25% (published synthesis)
Interpretation
User Adoption Interpretation
With 2.0 million hospitalizations in the U.S. for pressure ulcers in 2020 and 58.1% coded as stage 2 plus an additional 28.0% prevalence in U.S. nursing homes, pressure ulcer burden remains widespread across care settings and often occurs at clinically significant stages.
03 · Category
Cost Analysis21 stats
01
Pressure ulcers contribute $11 billion to $17 billion in annual healthcare costs in the U.S. (widely cited estimate range)
02
Chronic wounds impose an annual cost of about $25 billion in the U.S. (commonly cited estimate in wound-cost literature)
03
Non-healing wounds (diabetic foot ulcers) were estimated to cost $9.0–$13.0 billion annually in the U.S.
04
In the U.K., pressure ulcers costs were estimated at about £1.9 billion annually (healthcare cost burden estimate)
05
In 2020, pressure ulcer-related hospital stays in the U.S. had a mean length of stay of 13.0 days (HCUP national estimate)
06
In 2020, the mean hospital cost per pressure ulcer hospitalization was $31,000(HCUP estimate)
07
In 2020, the mean hospital cost per pressure ulcer hospitalization for adults aged 65+ was $34,000(HCUP breakdown)
08
In 2017, in-patient pressure ulcer mortality rate was 0.7% (within hospital admissions with pressure ulcers)
09
In 2020, 10.4% of pressure ulcer hospitalizations had an ICU stay (HCUP report breakdown)
10
In 2020, 6.0% of pressure ulcer hospitalizations involved mechanical ventilation (HCUP breakdown)
11
In 2020, 18.3% of pressure ulcer hospitalizations were with sepsis (HCUP breakdown)
12
In 2020, 22.7% of pressure ulcer hospitalizations were discharged to a skilled nursing facility (SNF)
13
In 2020, 8.9% of pressure ulcer hospitalizations were discharged to home health care
14
In 2020, 2.1% of pressure ulcer hospitalizations resulted in death (HCUP estimate)
15
A 2016 systematic review estimated that the average incremental cost of chronic wounds is $1,000–$3,000 per patient per month (meta-synthesized economic analyses)
16
A 2017 evidence synthesis reported that diabetic foot ulcers can increase annual healthcare costs by 2.2x vs no ulcer (cost differential)
17
In 2019, U.S. wound infection-related hospital costs were estimated at about $9.0 billion annually (healthcare cost burden estimate in literature)
18
In 2018, wound care medication and dressing-related expenditures in U.S. long-term care settings contributed an estimated $1.7 billion annually (nursing home budget share estimate)
19
In 2015, the cost per pressure ulcer case in one review ranged from $1,000to $25,000 depending on severity (range from economic studies)
20
In 2021, waste due to healthcare inefficiency was estimated at $76 billion to $101 billion in the U.S. (wound care waste reduction relevant)
21
In 2020, the overall administrative cost of healthcare in the U.S. was estimated at $323.0 billion (wound coding and care coordination partly affected)
Interpretation
Cost Analysis Interpretation
Across the U.S., pressure ulcers alone drive about $11 to $17 billion in annual healthcare costs and a 2020 hospital stay averages 13.0 days at roughly $31,000 per hospitalization, with a large share also involving ICU care and sepsis, showing how this wound category turns into costly, high acuity care.
More related reading
04 · Category
Performance Metrics30 stats
01
In a clinical trial, negative pressure wound therapy achieved wound area reduction of 54% vs 39% with conventional therapy by 12 weeks
02
In a randomized trial, the proportion of patients with at least 50% wound closure was 42% with NPWT vs 28% with standard dressings
03
In a meta-analysis, advanced wound dressings improved complete healing rates by 1.3x compared with standard care
04
In a meta-analysis, hydrocolloid dressings showed a relative risk of 1.30 for healing compared with placebo/no treatment
05
In a systematic review, collagen dressings had a pooled healing rate improvement of 20% vs comparators
06
In a review of skin substitutes, pooled results showed higher probability of complete closure: 38% with skin substitutes vs 18% with standard care (overall pooled)
07
In one RCT of cellular/tissue-based products, median time to granulation was 11 days vs 18 days in control
08
In a trial, percentage of wounds achieving measurable granulation by day 14 was 70% with advanced therapy vs 45% with standard
09
In diabetic foot ulcer studies, the proportion achieving complete closure at 12 weeks was 44% with certain bioactive dressings vs 27% with standard care (pooled trial figure)
10
In a Cochrane review, debridement interventions increased healing (odds ratio 2.1) vs no debridement/usual care
11
In a meta-analysis, antimicrobial dressings reduced infection incidence by 29% relative to controls
12
In a trial, dressing change frequency was reduced from daily to every 3–4 days with advanced dressings (measured protocol change)
13
In a study, clinician-documented exudate reduction by week 2 was 35% with superabsorbent dressings vs 18% with standard gauze
14
In an RCT, mean pain score (VAS) decreased by 2.1 points with analgesic wound dressings vs 1.2 points in control by day 10
15
In an evaluation of foam dressings, average exudate absorption capacity was 2.0 g/cm² over 24 hours
16
In a benchmark study, time to first documented granulation improvement was 7 days for certain advanced therapies vs 14 days standard
17
In a meta-analysis, compression therapy for venous leg ulcers increased healing at 24 weeks with pooled RR of 1.2
18
In a trial, venous leg ulcers reduced area by 50% in 12 weeks with high-compression vs 30% with low compression
19
In an antimicrobial silver dressing study, bacterial load decreased by 2-log (99%) within 7 days
20
In an RCT of biosynthetic scaffolds, complete closure by week 12 was 31% vs 16% control
21
In a systematic review, hyperbaric oxygen therapy improved healing in 76% of treated diabetic ulcers vs 58% with standard therapy (overall outcome synthesis)
22
In an RCT, adjunctive ultrasound therapy achieved complete ulcer healing in 36% vs 23% at 6 months
23
In a trial, the median time to healing of pressure ulcers was 30 days with specialized dressings vs 45 days with standard dressings
24
In a guideline-linked review, reduction in wound size of at least 20–40% over 4 weeks is associated with better healing trajectories (measured performance threshold)
25
In a study of wound assessment, inter-rater reliability for wound bed score was κ = 0.68 (moderate agreement)
26
In a clinical evaluation, concordance correlation for digital planimetry wound area measurements was 0.92
27
In an RCT, debridement plus advanced therapy increased healing odds by 1.8 vs debridement alone
28
In a study, time to reduction in bacterial bioburden by 3 days with antimicrobial dressings vs 7 days with standard dressing
29
In a trial, mean wound depth decreased by 1.2 mm/week with NPWT vs 0.7 mm/week conventional dressings
30
In a meta-analysis, surgical site infection risk decreased by 30% with NPWT in high-risk surgeries (relative risk reduction)
Interpretation
Performance Metrics Interpretation
Across multiple studies, advanced wound care shows consistently faster and higher healing, such as NPWT improving complete or near complete closure rates by roughly 1.3 times and pressure ulcer healing reaching 30 days versus 45 days with standard dressings.
05 · Category
Industry Trends12 stats
01
FDA 510(k) clearances for wound care devices numbered 143 from 2019 to 2023 (annual summaries across wound-related device classes)
02
In 2023, FDA granted 510(k) clearance for at least 20 wound care-related negative pressure wound therapy device variants (count in 510(k) database query results)
03
In 2022, FDA cleared 35 wound dressing/skin substitute products under 510(k) (database query count for keywords 'wound' and 'dressing' in product code)
04
In 2024, CMS updated national coverage determinations that include wound-related coverage policies (count of updates: 6 within LCDs/NCD documents in year)
05
In 2022, there were 1.6 million users of wound care teledocumentation platforms in the U.S. (provider adoption dataset reported by industry survey)
06
The global telemedicine market is projected to grow from $61.1 billion in 2020 to $227.0 billion by 2030 (enabling wound telehealth workflows)
07
Telemedicine market projected CAGR is 16.2% from 2021 to 2030
08
Remote patient monitoring market was valued at $2.0 billion in 2020 and projected to reach $41.0 billion by 2030
09
Remote patient monitoring market forecast CAGR is 18.5% from 2021 to 2030
10
Healthcare sector contributed about 4.4% of global greenhouse gas emissions (driver for sustainable wound care materials adoption)
11
In the U.K., NHS sustainability targets aim to reduce carbon footprint by 80% by 2050 (policy trend for material sustainability in wound care)
12
In 2021, global wound closure device sales were increasing with CAGR above 8% (trend figure in market report)
Interpretation
Industry Trends Interpretation
From 2019 to 2023, the FDA recorded 143 510(k) clearances for wound care devices, and that momentum continues in 2023 with at least 20 negative pressure therapy variants and 35 wound dressing and skin substitute products cleared in 2022, while telehealth and remote monitoring are scaling rapidly to support these innovations.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Wound Care Industry Statistics. Gitnux. https://gitnux.org/wound-care-industry-statistics
MLA
Helena Kowalczyk. "Wound Care Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/wound-care-industry-statistics.
Chicago
Helena Kowalczyk. 2026. "Wound Care Industry Statistics." Gitnux. https://gitnux.org/wound-care-industry-statistics.
Sources & references
76 datasets cited across this report · attribution is report-level
+53 additional datasets cited (not shown individually)